<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01224769</url>
  </required_header>
  <id_info>
    <org_study_id>RETRO-BENDA</org_study_id>
    <nct_id>NCT01224769</nct_id>
  </id_info>
  <brief_title>Bendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorders</brief_title>
  <official_title>A Retrospective Multicenter Trial on Efficacy and Toxicity of Bendamustine Alone or Associated With Rituximab, as Salvage Therapy in Patients With Chronic Lymphoproliferative Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Studio Linfomi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Studio Linfomi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This retrospective study collects and evaluates the clinical experience reached in Italy on
      the use of bendamustine alone or combined with rituximab as treatment of patients with
      relapsed or refractory chronic lymphoproliferative disorders.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>within 1 month after end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>grade III and IV (NCI Common Toxicity Criteria) adverse events</measure>
    <time_frame>within 1 month after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prognostic factors</measure>
    <time_frame>within 1 month after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>within 1 month after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>within 1 month after end of treatment</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">109</enrollment>
  <condition>Relapsed or Refractory Chronic Lymphoproliferative Disorders</condition>
  <arm_group>
    <arm_group_label>bendamustine +/- rituximab</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bendamustine +/- rituximab</intervention_name>
    <arm_group_label>bendamustine +/- rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with relapsed or refractory chronic lymphoproliferative disorders treated with
        bendamustine +/- rituximab
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with relapsed or refractory chronic lymphoproliferative disorders

          -  salvage treatment with bendamustine +/- rituximab

          -  age â‰¥ 18 years

        Exclusion Criteria:

          -  previous treatment with bendamustine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilio Iannitto, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gruppo Italiano Studio Linfomi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fortunato Morabito, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gruppo Italiano Studio Linfomi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefano Luminari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gruppo Italiano Studio Linfomi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gruppo Italiano Studio Linfomi</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2010</study_first_submitted>
  <study_first_submitted_qc>October 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2010</study_first_posted>
  <last_update_submitted>October 20, 2010</last_update_submitted>
  <last_update_submitted_qc>October 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2010</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

